Overcoming the challenges of drug discovery
The Challenges of drug discovery
When compared to traditional drug discovery timelines.
In 2020, Exscalate rapidly identified a lead compound for a new target in a dry eye indication, enabling a Harvard Medical School, Boston, spin-off, Aramis Biosciences, to go from zero to phase 2 investigational new drug (IND) approval of a new molecular entity (NME) in only 14 months. Read More
Exscalate embraces complexity
Extreme-scale virtual screening
Key advantages of Exscalate’s accelerated drug discovery platform
The speed at which complex interactions can be evaluated simultaneously in-silico allows for a platform that offers the highest quality and precision to ensure clinical success.
Advancing polypharmacology predictions
Complex diseases require complex therapeutic approaches. Exascale in-silico screening paves the way towards a new polypharmacological approach in which more effective drugs can be developed through modulating multiple targets.
Failing fast and adapt
Drug discovery traditionally entails substantial human effort only for it to end in failure during the clinical phase. The Exscalate platform anticipates failure far earlier in the process.
Unlike orthosteric modulation, which can lead to side effects, Exscalate modulates targets through an allosteric approach. This reduces side effects as it doesn’t block the receptor completely and enables the platform to attack “undruggable” targets.
Open to the scientific community
More than a platform, Exscalate is an open, barrier-less environment. It’s an environment that fosters collaboration with academic institutions, industry players and startups to deliver breakthrough science. Together we’ll create molecules of the future to cure disease.